Tdi-11861 (a fast-acting male contraceptive) approved for human clinical trials by the end of 2026?
Gesundheit & MedizinOne-Off2Mon
FutuurVerfügbarkeit prüfenVerifizierte AuflösungsdatenAktuelle implizite Wahrscheinlichkeit
Nein 93%
Nein 93%Marktqualitat
31 / 100
Niedrige Qualität24h-Volumen
—
Liquidität
247,9 €
Niedrige LiquiditätTrader
10
Kommentare
0
Marktdaten
Aktualisiert vor 1 Minute
Trends
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
How many clinical trials will have started in Prospera by Dec 31, 2026?
FutuurWill tabernanthalog (TBG) undergo Stage II clinical trials by EOY 2026?
Manifold MarketsWill a drug that didn't go through human clinical trials be approved by 2034?
Manifold MarketsWill it be possible to obtain FDA approval for a drug based on protein folding stimulations without human clinical trials by 2035?
Manifold MarketsWill human tooth regrowth clinical trials succeed?
Manifold MarketsIs Cheryl Scott from ABC CHICAGO pregnant????!?!??? 🤰
Manifold MarketsRegeln
Researchers Jochen Buck and Lonny Levin of Weill Cornell Medicine have discovered a fast-acting and temporary male contraceptive called tdi-11861.
- This substance, a soluble adenylyl cyclase (sac) inhibitor, works by stopping sperm from swimming, rendering the subject temporarily infertile.
- According to initial studies in mice, it takes effect within half an hour, and fertility returns within a day.
- However, despite the encouraging results in mice, more animal tests and human trials are required before it can be confirmed as a breakthrough in male contraception.
- This prediction market aims to determine whether tdi-11861 will be approved for human clinical trials before or on December 31, 2026.
- The outcome will be determined based on an official announcement from the relevant regulatory bodies or agencies, such as the FDA, or news reports from major news outlets that Futuur deems credible.
